For a long time, the effort of researchers and clinicians in the oncology field has been addressed to find sensible and specific cancer biomarkers or tests, allowing early cancer detection and better cancer management. The current biomarkers of liquid biopsy have been discovered many decades ago but only recently have been used in the management of cancer patients, maybe due to the limitations of available technologies.

As early as 1869, Ashworth [7] identified for the first time the circulating tumor cells (CTCs) in the metastatic cancer patient’s blood. In 1948, Mandel and Métais [8] recognized cell-free DNA (cfDNA) for the first time, but only in the 1970s, cfDNA was identified in cancer patients’ blood. In the 1960s, extracellular vesicles (EVs) were observed for the first time, but only in 2017, they were recognized as cancer biomarkers [9].

Even if they were discovered many decades ago, only in the last years they have captured the attention of scientific community as useful diagnostic tools, due to the diffusion of commercial and homemade liquid biopsy tests [10]. In fact, the development of sequencing technologies and the improvement of cancer genomic knowledge [11] lead to the diffusion of several comprehensive genomic profiling assays to personalize cancer patients’ management, promoting the diffusion of liquid biopsy.

The concept of the liquid biopsy appears in the 1970s on Pubmed platform referred to the analysis of CTCs from the blood of patients affected by different solid tumors, but only in the last decade the number of articles about liquid biopsy has increased progressively, up to the present days when the literature about liquid biopsy is extremely wide (Figure 1) [12–33].

The term liquid biopsy is usually applied to blood samples mainly for the analysis of ctDNA and in part of CTCs, but many other biomarkers and types of samples are emerging [34].

The tumor microenvironment includes a mix of cellular and non-cellular components, many of which are released from cancer cells, which contribute to cancer survival, invasion, metastatic process, and resistance to treatments. Among these components, CTCs, ctDNA, cfDNA, EVs, or exosomes stood out for their characteristics as useful biomarkers circulating in the peripheral blood of cancer patients.

In blood samples, both in the plasma or serum, and in the cellular fraction, different circulating biomarkers can be detected and characterized [6].

In the plasma or serum, tumor-derived EVs or exosomes [35], proteins, circulating noncoding and messenger RNA [circulating free RNA (cfRNA)] [36], ctDNA [37], and tumor-educated platelets (TEP) [38, 39] can be detected. In the cellular fraction, single CTC and CTC clusters (constituted with CTCs exclusively or with CTCs escorted by immune cells) [40], circulating endothelial cells (CEC) [41], and cancer-associated (CA) fibroblasts can be identified [6]. Leukocytes and T-cell receptor profiling may also be potential biomarkers for metastatic patients treated with immunotherapy [42, 43].

The liquid biopsy biomarkers are present also in different body fluids, expanding the concept of liquid biopsy not only to the peripheral cancer patients’ blood but also to other fluids like prostatic fluid, urine (particularly for renal, bladder, and prostate cancers) [44], cerebrospinal fluid (CSF, particularly for central nervous system metastasis and primary brain cancers) [45], saliva or sputum, pleural effusion (particularly for head and heck and lung cancers) [46], tears, bile, peritoneal lavage, and bone marrow (particularly for breast, prostate, and lung cancers), stool, breast milk, and ascitic fluid [47–49].

The CTCs are cancer cells with a median half-life of 1–2.5 h, released in the blood from the primary tumor or metastatic sites at any stage of tumorigenesis [50]. They are present in the circulation as individual cells or in clusters (in this case, they have an increased metastatic ability). The CTCs have a high heterogeneity, according to their genomic, transcriptomic, proteomic, and metabolomic characteristics [51] and their phenotypic aspect depends on cancer type and stage of disease (usually associated with the worst prognosis) [52]. Their interactions with blood and tissue components are crucial for cancer survival and promotion of metastatic disease. The CTC blood concentration is very low and metastatic patients may have 1–10 CTCs per mL of blood [53].

Due to the very low concentration of CTCs, their analysis is difficult, expensive, and technically challenging. Complex technologies are needed to isolate and analyze CTCs and many platforms and assays have been developed for detecting CTCs through recognition of cell size, or expression of cell-surface antigens. In fact, CTC isolation requires different steps such as enrichment, detection, and cell characterization [54–57]. The enrichment step is based on the identification of their physical (size, elasticity, and density) and biological properties to increase CTC concentration. The detection step is based on immune-cytologic, molecular, or functional assays [54, 57, 58]. In the end, the CTC characterization is possible and CTC cultures, CTC lines [59–61] and CTC xenografts can be established [62–64]. There are several commercial assays for the enrichment, detection, and characterization of the CTCs. The CellSearch^® system is the most used and it is the only FDA-approved assay for searching CTCs [65]. The EPithelial ImmunoSPOT (EPISPOT) assay is also a clinical validated assay for many different cancers, including breast, prostate, head and neck cancers, and melanoma [66–68]. Other examples of CTC commercial assays for the liquid biopsy are Oncotype diagnosis (DX) androgen receptor splice variant 7 (AR-V7), oncotype sequencing (SEQ), Adnatest^®, Epic Sciences, RareCyte, and EPithelial ImmunoSPOT in a DROP (EPIDROP). The CellSearch^® system was approved by FDA in 2004 to predict outcomes in metastatic breast cancers. In 2013, FDA expanded the indication of CellSearch^® CTC enumeration platform, to monitor patients with colon and prostate cancers [69–71]. In fact, the CTCs have been detected and studied in several different types of cancer, but their role as useful biomarker to predict outcomes, identify MRD, guide therapeutic choice, and monitor cancer progression is more evident in breast, prostate, colon, and lung cancer patients [40, 72–75].

The identification of CTCs allows the preservation of cellular contents and the expression of gene information, consenting functional analysis of CTC cultures, molecular characterization of genome, and protein analysis [76]. For example, the expression of AR-V7 splice variant on the CTCs of metastatic prostate cancer patients strongly predicts the resistance to abiraterone and enzalutamide [77]. Different studies have demonstrated that CTC’s functional and molecular characterization may have a prognostic value in cancer patients and may indicate the tumor’s capacity to become metastatic [53]. They are also associated with shorter progression-free survival (PFS) and overall survival (OS; metastatic breast, colorectal, and prostate cancers), as well as they may be used to monitor cancer evolution and response to therapy [78, 79]. In fact, the CTCs appeared to be generally more expressed in aggressive diseases [80, 81]. In addition to the prognostic value, their molecular characterization can provide additional information about the site of CTC origin (different organ microenvironments can select different types of CTCs), the ability to disseminate, the drug susceptibility or resistance in cell culture or xenograft, and the transcriptional plasticity [80–82].

Furthermore, the whole genome analysis (WGA) of a single CTC has shown great variability, confirming the tumor heterogeneity [83]. Based on these considerations, a blood sample may contain multiple cellular subpopulations and the analysis of a single CTC may not be representative of whole tumor biology [84].

However, CTCs are very difficult to detect due to the very complex and expensive method and the small number of cells in the blood at the early stage of diagnosis, during follow up and in the metastatic disease (often < 1 CTC per mL of blood). For these reasons, CTCs have limited clinical utility [85–89]. Further studies are needed to better understand the role of CTCs in the oncological precision medicine and detection technologies needed to be improved.

The tumor-derived EVs or exosomes are small round vesicles, generally 30–120 nm in diameter, delimited by a lipid bilayer that carries out proteins, DNA, RNA, small non-coding RNAs [microRNA (miRNA)], and lipids [53, 90, 91]. They are released by the tumor cells and used for communication between the tumor and other different cells [92, 93]. Each cancer cell type secretes a specific EV, allowing it to determinate the presence of the cancer and the cancer type [94, 95]. They are also found in abundant quantities in biological fluids, increasing the detection sensitivity [39, 93, 94]. The lack of unified adequate isolation methods and standardized analysis is a great limitation of EV implementation in the clinical setting [96]. The most diffused EV isolation technique is ultracentrifugation (UC), which separates EVs based on their size and density, and it requires dedicated equipment, excessive time, and costs [97]. The combination of different procedures, such as ultrafiltration and density gradient centrifugation, can increase the quality of EV isolated but can also reduce the amount of EVs [98–101]. In the last years, many commercial isolation kits have been developed trying to save time but with high costs [102].

Despite these limitations, EVs have been used as a novel biomarker in liquid biopsy for cancer monitoring, staging, and as a prognostic and dynamic tool for cancer therapy management [10, 93–95, 103–107]. However, the advantage of EV application to clinical settings is related to their various cargoes, allowing the identification of different and more specific molecular targets necessary for a personalized treatment [93–95]. The most common EV marker is the RNA and, in particular, the miRNA signature as predictive biomarker of prognosis and survival in different tumors, such as lung [108–110], liver [111, 112], colorectal [113], prostate [114], hepatocellular [115], breast [116], and pancreatic [117] cancers [10] and glioma [118]. For their nature and role, EVs can also be used to target tumor cells and to deliver and transfer drugs such as chemotherapies or immunotherapies in other cancer cells [10, 119–121]. For these reasons, recently, EVs are recognized as a promising potential liquid biopsy resource in oncology, but standardized and convenient methods for isolation are needed [91, 122].

The attention of the scientific community to the role of EVs as biomarkers for liquid biopsy in cancer is relatively recent, so further studies are needed to better understand their clinical utility in the oncological field.

The DNA is released in fragments (cfDNA) through apoptosis, necrosis, and active secretion by normal (particularly lymphoid and myeloid cells, due to the frequent turnover of hematopoietic lineage cells of blood) [123], and cancer (ctDNA) cells [34, 37, 124, 125]. The concentration of ctDNA might only be < 0.01% of total cfDNA [58, 126]. The ctDNA is constituted of small DNA fragments (180–200 bp) released in the bloodstream of cancer patients. It has a short half-life (from 15 min to about 2.5 h) and a concentration range from 0 ng/mL to 1,000 ng/mL in blood (an average of 180 ng/mL in cancer patients) [125, 127, 128]. The fragment size of the ctDNA is variable, according to the different release mechanisms in the blood and the incomplete and random digestion of the ctDNA. The concentration and length of the ctDNA fragment can be a signature for prediction, diagnosis, and prognosis in cancer [129–133]. The ctDNA concentrations are higher in patients with metastatic cancers than those with localized cancers [134]. It is cleared through nucleosomes in the liver (liver macrophages), by circulating nucleases and in the kidney [124, 125, 129, 133, 134]. However, ctDNA shedding depends on several factors, like the tissue cell turnover (proliferation and apoptosis rate), the burden of disease, and the tumor site [124, 125, 129, 133, 134].

For its nature, the ctDNA provides information about point mutations, copy number variations (CNVs), structural rearrangements, loss of heterozygosity, gene fusions, methylation changes, integrated viral sequences associated with the tumor, and other genomic signatures [135–139].

The variant allele frequency (VAF) describes the proportion of ctDNA molecules containing a mutation over the total number of molecules containing the same allele [140–142].

The ctDNA recapitulates with accuracy the tumor characteristics and appears to be a diagnostic tool for many different solid tumors, for example, colorectal [143, 144], endometrial [145, 146], ovarian [78], breast [147], non-small cell lung cancer (NSCLC) [148–150], oropharyngeal [151], pancreatic [152], prostate [153, 154] cancers, and melanoma [155].

Currently, the ctDNA is the preferred biomarker for liquid biopsy analyses of druggable mutations. In fact, it can overcome costs, limitations and the difficulties in identification, extraction, and characterization of CTCs and EVs. Recently, a great number of technologies and commercial assays have been rapidly developed to detect ctDNA, and numerous studies have spread to investigate the potential role of this biomarker.

In the metastatic setting, the therapy decision-making process needs the genomic tumor analysis at the diagnosis and at the restaging of the disease [6]. In the targeted therapy era, the detection of druggable molecular alterations and the respective tailored treatment options can improve patient outcomes [218].

Despite the tissue biopsy is a gold standard technique for cancer diagnosis and molecular characterization, the liquid biopsy can be a complementary and even an alternative tool, considering a good concordance between the two methods and the high specificity and the moderate sensitivity of the latest one [174, 219–225]. For these reasons, the companion diagnostic tests have spread in the routinely clinical practice, particularly when the tissue is unavailable or insufficient (to search clonal alterations) and to detect acquired resistance mechanisms to therapy (to search clonal and subclonal alterations) [199, 226].

The NCI defines the companion diagnostic test as “a test used to help match a patient to a specific drug or therapy. For example, a companion diagnostic test may identify whether a patient’s tumor has a specific gene change or biomarker that is targeted by the drug. This helps determine if the patient should receive the drug or not. Companion diagnostic tests can also be used to find out whether serious side effects may occur from treatment or how well the treatment is working. Most drugs with a companion diagnostic test are cancer drugs that target specific tumor mutations.” [227]. Many guidelines have been developed to help clinicians in the use of the liquid biopsy, mainly for the interpretation of its results, such as ESMO recommendations and OncoKB recommendations [including FDA labeling, National Comprehensive Cancer Network (NCCN) guidelines, conference proceedings, disease-focused expert group recommendations, and the scientific literature] [181, 191, 193, 228].

The advanced NSCLC adenocarcinoma is the best example for the liquid biopsy application in molecular cancer profiling at the time of diagnosis [such as EGFR, ALK, c-ros oncogene 1 (ROS1), v-raf murine sarcoma viral oncogene homolog B1 (BRAF), MET, rearranged during transfection (RET) analysis)], when the tissue is insufficient for the molecular testing (about 50% of the cases) [181, 229] and a new tissue biopsy cannot be performed, or at the time of progressive disease after a targeted therapy with tyrosine kinase inhibitors (TKIs) [200, 201, 230]. For both purposes, the liquid biopsy has been integrated into the recommended guidelines and many companion diagnostic tests are available (such as Guardant360^®, FoundationOne^® Liquid CDx, and Cobas). It has been shown that ctDNA assays can detect guideline-recommended biomarkers with a high concordance with the tissue analysis, and the power of detection increases when tissue and liquid biopsy are used complementary [163, 231]. The ctDNA can identify the acquired molecular resistances developed after treatment with EGFR TKIs (first or second generation), such as EGFR T790M mutation, and can guide the subsequent therapeutic choice (osimertinib) [232]. When osimertinib is prescribed in the first line therapy, EGFR C797S, BRAF V600E mutation, MET amplification or amplification or human epidermal growth factor receptor 2 (HER2) amplification can be detected in liquid biopsy as acquired resistance alterations [233–237]. In the metastatic EGFR-mutant patients, when the EGFR-positive ctDNA was detected after six weeks of osimertinib and bevacizumab treatment, it identified patients with high risk for early progression and lower OS [238]. The ctDNA analysis can also identify ALK fusion and related acquired resistance alterations, guiding the target therapies with TKIs [239], such as for ROS1 [240] and MET molecular alterations [241]. Also, for ALK TKI therapies, the liquid biopsy may be a surrogate of outcomes, predicting the therapy response, according to the clearance of the blood ctDNA [242]. The emergence of HER2 and Kirsten rat sarcoma (KRAS)^G12C alterations powered the use of the liquid biopsy in the choice of the targeted therapy [241–245].

Anyway, if the liquid biopsy is negative (EGFR T790M, exon 19 deletion, and/or exon 21 L858R mutations and/or ALK fusion are not detected in ctDNA analysis, for example), a tissue testing is recommended [229, 246].

Furthermore, the NGS panels can also detect a plethora of unexpected molecular alterations of known or unknown meaning, that could give information about cancer evolution. Unfortunately, the NSCLC can switch under target therapeutic pressure to SCLC. In this scenario, the liquid biopsy is useless and the tissue biopsy is necessary [247].

In the HER2-negative and hormone receptor-positive (HER2–/HR+) metastatic breast cancer, the detection of PIK3CA mutations with the liquid biopsy can guide therapeutic choice with cyclin-dependent kinases 4/6 (CDK4/6) inhibitor alpelisib in combination with fulvestrant after endocrine therapy progression. Even in this case, when the ctDNA PIK3CA is negative, the tissue analysis is always necessary [248, 249]. The FDA approved as companion diagnostic test the Therascreen^®, PIK3CA RGQ PCR Kit for the detection of the PIK3CA mutations with the liquid biopsy in breast cancer patients with this setting, based on the results of SOLAR-1 trial [249]. Furthermore, in HER2 mutant non-amplified metastatic breast cancer patients treated with neratinib, the liquid biopsy in NGS demonstrated 100% specificity [250]. In the clinical trial plasma-based molecular profiling of advanced breast cancer to inform therapeutic choices (plasmaMATCH), the ctDNA was used for randomized patients in 5 cohorts based on mutation profiles [251]. In estrogen receptor-positive (ER+) metastatic breast cancer patients, the identification of estrogen receptor 1 (ESR1) and phosphatase and tensin homolog (PTEN) alterations by liquid biopsy is associated with the intrinsic resistance to aromatase inhibitors and alpelisib treatment [252].

For the metastatic colorectal cancer (mCRC) the NCCN guidelines do not directly address ctDNA tests and ESCAT guidelines consider the NGS only an alternative option to the PCR if it does not result in additional costs [228]. Despite this, the ctDNA was used for studying resistance mechanisms of cancer for the first time and showed high concordance with the tissue analysis [179, 253–256]. In the mCRC, the ctDNA liquid biopsy has shown its clinical utility in guiding first-line therapeutic choice by identifying rat sarcoma (RAS) mutations, which are negative biomarkers of response to anti-EGFR monoclonal antibodies therapy. The KRAS and neuroblastoma RAS viral oncogene homolog (NRAS) are also often acquired resistance alterations to target therapy and their identification is important for the re-challenge option with the anti-EGFR therapy in advanced lines [185, 255–259]. The BRAF V600E mutation detected by the ctDNA plays an important role in the choice of combined BRAF and EGFR inhibitors targeted therapy. This genomic profiling detection is important for the evaluation of acquired resistances to target therapy, too [260–262]. The mCRC is the best example to show the clinical utility of the ctDNA to identify and assess spatial and temporal heterogeneity in cancer [263]. In contrast to the tissue analysis, the ctDNA liquid biopsy gives an instantaneous collective snapshot of the cancer heterogeneity from all sites of cancer and at different time points in the history of a cancer patient [264–266]. An example of the cancer spatial heterogeneity of different metastatic sites is shown by the study of Parikh et al. [205] about mCRC patients, in which the post-progression ctDNA liquid biopsy captured all the acquired resistance alterations, that were later found separately in the distinct metastasis lesions by tissue biopsies. Siravegna et al. [267] showed how the ctDNA liquid biopsy can identify the different genomic evolution of each metastasis in mCRC, treated with HER2 blockade therapy [trastuzumab and lapatinib on the HER2 Amplification for Colo-rectaL cancer Enhanced Stratification (HERACLES) study]. They also showed how the ctDNA may help to understand the mixed radiological responses, highlighting the heterogeneity of anatomical response to the targeted therapy [261, 267]. An example of the cancer temporal heterogeneity [268, 269] is given by Parseghian et al. [270] study in which in the mCRC RAS wild type patients, after discontinuation of anti-EGFR antibodies, the ctDNA liquid biopsy predicts the decline of KRAS mutant-clones and provides evidence for re-challenge therapy with the anti-EGFR antibodies. Anyway, further studies are needed to validate the results of liquid biopsy as a tool to identify actionable molecular alterations to detect and manage the cancer’s spatial and temporal heterogeneity.

In 2020 the FDA approved the FondationOne liquid CDx as a companion diagnostic test for the use of rucaparib in BRCA-mutated mCRPC patients, demonstrating the feasibility and utility of the ctDNA in clinical practice also for this cancer type [182, 271].

In advanced melanoma, the liquid biopsy can improve the identification of BRAF and receptor tyrosine kinase (KIT) mutations for targeted therapy choice [272]. The BRAF V600 mutations were detected with the liquid biopsy in patients treated with BRAF and mitogen-activated protein kinase kinase (MEK) inhibitors before the radiological progression, with the lead time reduction of 110 days [273].

The PDL1 expression as a biomarker to select patients for immunotherapy remains limited for few cancer types and its determination requires tissue biopsy. The FDA approved pembrolizumab for genome signatures microsatellite instability-high (MSI-H) and high tumor mutational burden (TMB, ≥ 10 mut/Mb) in different tumors [274–276]. Some ctDNA assays can explore TMB and MSI status, overcoming the sampling bias and allowing pembrolizumab therapy with liquid biopsy analysis [206, 277, 278]. Particularly, the study that used ctDNA Guardant360^® assay to identify the MSI-H status showed clinical benefit from anti-PD(L)1 antibody therapy [277]. Wang et al. [279] have demonstrated that it is necessary a high-quality DNA to avoid underestimation of TMB for a correct clinical evaluation. Chauhan et al. [280] have detected and calculated the TMB from the ctDNA in urine rather than in blood [281]. Although many different guidelines (such as NCCN and ESMO guidelines) do not address plasma-based testing TMB or other tumor agnostic biomarkers like neurotrophic tyrosine receptor kinase (NTRK), the ctDNA analysis can help to choose the best treatment in selected cases [194].

Cancer resistance evolves dynamically under targeted therapy selective pressure and the ctDNA liquid biopsy can be a useful tool to detect these mechanisms of resistance [82].

The usefulness of the ctDNA has been explored in many studies in different settings, including prognosis and treatment response monitoring [282–286]. The response monitoring using the ctDNA was born to track actionable oncogenic alterations during the targeted therapy. The feasibility of the ctDNA for this purpose became evident in different tumor types and in several settings [287, 288]. The monitoring of treatment response is also important to avoid ineffective therapies and unnecessary side effects. Moreover, many studies have analyzed the ctDNA value as a prognostic marker for clinical outcomes and as a tool for monitoring treatment response [289–291].

In the routine practice, the imaging is used to monitor treatment response sometimes in association with the tumor markers, unfortunately, their use is limited in sensitivity and specificity [58]. The ctDNA could be used as a personalized tumor-specific marker for patient surveillance and treatment efficacy monitoring [170, 270, 292]. Although the ctDNA has many issues, such as limited tumor shedding and burden of disease, the dynamic liquid biopsy can allow to monitor not only the tumor response but also the tumor evolution. Furthermore, in many scientific articles, the ctDNA decreasing or increasing clearance is associated with cancer response or progression to therapy respectively, with a shorter leading time than imaging [170, 270, 292, 293].

For example, in advanced EGFR-mutated NSCLC, early changes in the ctDNA value under targeted treatment with osimertinib providing efficacy information, particularly early clearance or decreasing levels of the ctDNA EGFR mutation (also known as molecular response) were associated with subsequent imaging response and with an improvement in response rates (RRs), PFS, and OS [294–296]. Conversely, higher ctDNA levels were associated with poor prognosis [297]. Several groups have demonstrated that early decreasing or clearance of the ctDNA in advanced NSCLC treated with immunotherapy or immunochemotherapy was associated with longer OS and a high RR, conversely increasing ctDNA, was correlated with the disease progression [170, 206, 298–300]. The ctDNA dynamics may also help to identify immunotherapy pseudoprogression, detecting a decrease of ctDNA levels versus increased tumor radiological volume, and conversely detecting an increase of ctDNA in true tumor progression [301]. Despite the diffusion of many works with similar results, further studies are needed to better investigate the role of the ctDNA as a biomarker for therapy response in different solid tumors.

In the metastatic breast cancer, the early ctDNA detection can predict response to palbociclib and fulvestrant therapy [302]. It can also predict therapy response and prognosis in the early breast cancer patients receiving neoadjuvant chemotherapy. In fact, the patients with positive ctDNA before neoadjuvant chemotherapy had significantly shorter disease-free survival (DFS) and OS than those with negative ctDNA [303].

In the advanced pancreatic cancer, a decrease of KRAS mutant ctDNA identified an earlier tumor response to the therapy, and it is strongly associated with clinical outcomes than blood levels of tumor markers [304, 305].

In a study by Lim et al. [306] conducted in RAS wild-type mCRC patients treated with chemotherapy and anti-EGFR antibody, the changes of the ctDNA VAF had linear correlation with tumor size and clinical outcome [307]. Moreover, in the KRAS mutant mCRC patients, the increasing ctDNA KRAS mutation allows to detect progression of disease earlier than imaging [308].

The dynamic ctDNA can correlate with outcomes and with radiological responses also in melanoma patients. Already in 2015, Gray et al. [309] evaluated the ctDNA to monitor treatment response in metastatic melanoma patients treated with targeted therapy or with immunotherapy. The patients who had persistently elevated ctDNA on both therapies had a poor prognosis; conversely, the decreasing or clearance of ctDNA at the first imaging follows up correlated with a better prognosis.

Anyway, the ctDNA has yet several limitations that must be overcome and many interventional clinical trials are needed to investigate its real clinical value, so the ctDNA is not actually used for monitoring treatment response or for prognostication in clinical practice and this remains an active challenge [310].

The National Institutes of Health (NIH) defined the MRD as “a very small number of cancer cells that remain in the body during or after treatment. MRD can be found only by highly sensitive laboratory methods that are able to find one cancer cell among one million normal cells. Checking to see if there is MRD may help to plan treatment, find out how well treatment is working or if cancer has come back, or make a prognosis. MRD testing is used mostly for blood cancers such as lymphoma and leukemia, also called MRD.” [311].

Therefore, the MRD represents the detection of residual cancer cells (for example, ctDNA) without evidence of cancer disease at the conventional tests (for example, imaging, protein cancer biomarkers) during routine surveillance, after complete resection, neoadjuvant and/or adjuvant therapies [312]. If the cancer cells are still present after treatment, they may induce a relapse of disease. The MRD can help to classify patients with high or low risk of relapse and to predict short- or long-term relapse [313, 314]. The utility of the liquid biopsy to identify MRD is evident, considering the absence of other tools that can detect microscopic disease and its capacity to identify residual disease with a lead time of several months earlier than imaging. Moreover, the liquid biopsy can guide treatment adjustment and the surveillance during or after a curative treatment (for example, surgery and adjuvant chemotherapy) [315].

Although many different studies have investigated the clinical utility of the ctDNA to search the MRD, many limitations have been highlighted. For example, the MRD cannot be assessed by standard clinical and imaging technologies, the CHIP may be a confounding factor [316, 317], the timing of the ctDNA sampling between surgery and starting adjuvant therapy is often a crucial challenging point because it is difficult to choose the best moment (not too soon to detect the ctDNA set free from surgery, but not too late to start therapy) [318]. It is also very difficult to detect the ctDNA at a very low concentration with standard ctDNA non-personalized and uninformed assays, due to low sensitivity and lack of standardization of methodologies and technologies. Recently, many personalized informed technologies are developed to detect the MRD accurately, sequencing single tumor genotypes and designing a PCR or a NGS assay tailored to each patient. Tumor-informed ctDNA analysis is more sensitive than tumor naive analysis, but it is expensive and less feasible for clinical practice [310, 319, 320]. Examples of commercial panels to detect the MRD are Signatera^TM [Natera/Foundation Medicine (FMI)], Archer^®Dx/Invitae-personalized cancer monitoring (PCM) assay, Guardant Reveal (LUNAR 1), Roche Avenio ctDNA surveillance kit, Inivata RaDaR/InVision MRD kit. Anyway, in a few years studies and clinical trials are increasingly trying to overcome these limitations and to select the best clinical and treatment approach in this new field [320–324].

Researchers have investigated the role of the ctDNA in the MRD not only for prognosis, but mainly for evaluated escalation or de-escalation treatments [325]. In patients with the MRD detected by the liquid biopsy after a curative treatment, an intensification or escalation treatment may be an optional strategy to improve DFS and OS. Conversely, in patients with the absence of the MRD after a curative treatment, a de-intensification or de-escalation therapy (such as omitting or depowering the adjuvant therapy schedule) can reduce side effects or toxicities [314, 326, 327].

In the NSCLC, adjuvant treatment has a modest survival benefit, thus the MRD can help to select the patients that really benefit from therapy [328, 329]. The TRACERx study has shown that the ctDNA MRD-positive predicted relapse before conventional imaging, with a median time of 164 days versus 362 days of imaging, with a significant lead time [330].

The DYNAMIC study evaluated the ctDNA dynamics after radical surgery, highlighting that the ctDNA MRD detected 3 days after surgery (R0) may be used as a baseline for lung cancer monitoring [331, 332]. The ctDNA can be used also in the unresectable locoregionally advanced NSCLC, to guide the escalation or de- escalation treatments. Moding et al. [333] have found that the detection of the ctDNA after chemoradiotherapy (CRT) or early on consolidation with the durvalumab was a strong predictor of risks of progression of disease. In contrast, the patients with the ctDNA not detected after CRT had better outcomes with or without consolidation immunotherapy, identifying patients in which therapy can be de-escalated [333]. A great number of studies are ongoing to better understanding where patients can benefit from adjuvant therapy and are cured by surgery alone, investigating the role of the ctDNA MRD in the management of the early-stage NSCLC.

The role of the ctDNA liquid biopsy has been evaluated for further different tumors. Garcia-Murillas et al. [334, 335] showed that, in the early breast cancer patients, the detection of the ctDNA after a curative therapy was associated with the metastatic recurrence, with a median lead time of 7.9 months over imaging and clinical recurrence.

Another study showed that in the ctDNA-positive muscle-invasive urothelial cancer patients, the adjuvant immunotherapy with atezolizumab can improve survival [336].

In the early CRC, a great number of studies have shown the utility of the ctDNA to detect the MRD and its role as a prognostic factor [337–341]. Reinert et al. [342] have shown that stage I–III CRC patients, with ctDNA- positive after a definitive therapy, had an increased risk of recurrence (about 40 times) than ctDNA negative patients during the follow-up. Notably, the lead time of the disease recurrence was 16.5 months (with respect to the imaging). Tie et al. [343] showed that, in locally advanced rectal cancer, the post-surgery ctDNA detection was strongly predictive of recurrence [344]. Tie et al. [345] also showed that in stage III CRC, the post-surgery ctDNA positive patients have a poor outcome, despite adjuvant therapy, with a 3-year-recurrence-free interval of 47% versus 76% in the ctDNA negative patients. Loupakis et al. [346] have evaluated the mCRC patients who had undergone metastatic resection with curative intent (PREDATOR clinical trial). The postsurgical MRD status was a strong prognostic biomarker associated with DFS. In fact, the MRD-positive patients had an inferior OS than the MRD-negative ones, also, the MRD-negative patients who did not receive systemic therapy had an OS of 100%.

The ctDNA has also been evaluated as a prognostic biomarker for the risk of the assessment in many different cancer types, as described above.

In another study, in the I–III stage NSCLC patients, the pre-surgery ctDNA detection identified patients at a higher risk of recurrence, which may reflect the micrometastatic disease [347].

Moreover, in the metastatic triple-negative breast cancer, the tumor fraction ≥ 10% was associated with a significantly worse survival [348].

In the metastatic BRAF V600 mutant melanoma, the BRAF ctDNA negative-patients at baseline therapy had a high RR to target therapy, while the BRAF-positive patients had a shorter PFS and OS [349].

Several studies have investigated the role of the ctDNA as prognostic biomarker, and many studies identified poor prognosis associated with high ctDNA levels.

Even if the ctDNA MRD may become a real-time biomarker for relapse of disease, many clinical questions are still open [210, 310, 350].

A great number of studies are ongoing in this field trying to delineate clinical utility of the liquid biopsy in the MRD.

The use of the ctDNA liquid biopsy in cancer early detection and screening is further investigated [351–355]. The liquid biopsy is a minimally invasive test, which can be repeated multiple times, and the blood draw is well accepted by people. However, in this setting further limitations arise due to the type of the population studied.

First, in the early detection and screening setting, a positive liquid biopsy identifies an “occult” cancer, with unknown origin, not detected by clinical and imaging standard. The detection of the CHIP mutations can give false positive results, limiting the specificity of the test in a setting in which high specificity is required high specificity. Furthermore, in the early cancer stage, the tumor burden is very low and consequently, the ctDNA levels are very low, giving false negative results due to the limited sensitivity of assays [330]. Additionally, some sensitive and specific tests are very expensive [356]. So, the liquid biopsy can over-diagnose or under-diagnose, or can just give an unclear clinical result, limiting its utility [310].

Multiple assays have been developed to implement the liquid biopsy as a good cancer screening test, such as the new ultrasensitive assays or using methylation markers.

Cohen et al. [357] have demonstrated the value of the liquid biopsy CancerSEEK platform for early detection of 8 different cancers, and its specificity was > 99% and sensitivity was 69–98% (all patients knew to have cancer).

The combination of different diagnostic approaches was investigated by Lennon et al. [216] in the Detecting Cancers Earlier Through Elective Mutation-Based Blood Collection and Testing (DETECT_A) study, using a multicancer test coupled with positron emission tomography/computed tomography (PET/CT) imaging to detect early cancer (no patient knew to have cancer), confirming the potential utility of this approach.

The ctDNA levels in the early-stage patients are lower than those in metastatic patients [330], and the sensitivity of a test is also given by both the blood volume sampled and by the number of mutations analyzed [358], so many commercial panels for early cancer screening probes multiple mutations [359].

Despite many limitations, the liquid biopsy can be a helpful tool for the cancer screening when other methods are not available, or patients refuse or are not fit for them.

The FDA has approved some liquid biopsy tests for the cancer screening, such as the Epi proColon^® for CRC, and have designed other liquid biopsy tests breakthrough device, such as the Grail’s Galleri, Natera’s Signatera^TM, and CancerSEEK multicancer test, to support the current standard screening tests. The Epi proColon^® (Epigenomics) is a blood-based screening test, available for patients with an average risk of CRC, who have not completed the conventional guideline-recommended screening (unwilling or unable). It detects the tumor-associated epigenetic changes [360–362]. The CancerSEEK is a blood-based screening test; it identifies 8 different early-stage cancer types (breast, colon, esophagus, lung, liver, ovary, pancreas, and stomach), complementing other screening standard tools. It detects 8 biomarkers and mutations on 16 genes [363].

Furthermore, the liquid biopsy on urine may be useful for screening, and tests such as the UroSEEK or UroVysion have developed [364]. The UroSEEK detects mutations in 11 genes and aneuploidy for the identification of bladder and upper urothelial cancers. It has a sensitivity of 83% [365].

The early diagnosis remains a challenge, with sensitivity, specificity, and costs as critical factors. The liquid biopsy in this setting needs to overcome technical and clinical challenges. Further interventional and prospective, large-scale clinical trials are needed to demonstrate the clinical utility and the positive predictive value for cancer screening.